Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs SoundHound AI Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while SoundHound AI Inc trades at $6.71 (market cap $2.88B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | SOUN | |
|---|---|---|
Market Cap | $4.49B | $2.88B |
Sector | Health | Technology |
52-Week High | $28.06 | $21.40 |
52-Week Low | $20.06 | $5.90 |
Enterprise Value | $3.69B | $2.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SoundHound AI (SOUN) trades at $6.96, up 6.26% on the day, with a bearish technical signal despite recent positive earnings beats. The company shows strong revenue growth in auto and IoT AI segments, up 88% year-over-year in Q1 2026, but faces profitability challenges with a net income margin of -91.84% and negative cash flow from operations. Analyst sentiment remains bullish with a $13.00 consensus price target, though the stock is down 37% year-to-date amid concerns over the LivePerson acquisition and high valuation multiples.
The outlook hinges on SOUN's ability to achieve profitability through scaling and cost synergies from acquisitions. Investment opportunities include market expansion in telecom and energy sectors, while risks involve persistent cash burn, competitive pressures, and execution risks in integrating LivePerson. The stock's high short interest could lead to volatility, but analyst optimism suggests potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
